Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Date:4/21/2009

- Pharmacologic Data Presented at American Association for Cancer Research's 100th Annual Meeting 2009 -

SOUTH SAN FRANCISCO, Calif. and DENVER, April 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the presentation of final data from a Phase 1 clinical study of an oral formulation of picoplatin in patients with solid tumors. Results showed that the bioavailability of oral picoplatin is nearly 100 percent at doses of 50 mg and 100 mg, indicating sufficient bioavailability to support further clinical development.

Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent in clinical development to treat a variety of solid tumors. It was designed to overcome platinum resistance of the tumor, which remains a medical challenge for oncologists and patients, whose therapeutic options become limited. Poniard is currently evaluating an intravenous formulation of picoplatin in a pivotal Phase 3 trial in patients with small cell lung cancer (SCLC) and in Phase 2 trials in metastatic colorectal cancer (CRC) and metastatic castration-resistant prostate cancer (CRPC).

"The results of the Phase 1 trial demonstrating the oral bioavailability of picoplatin support the continued development of an oral formulation for multiple tumor indications," said Robert De Jager, M.D., chief medical officer of Poniard. "We believe that oral picoplatin may offer opportunities for studies in new indications and in combinations with other chemotherapeutics or with radiation therapy. The administration options for oral picoplatin may provide more convenience to cancer patients and could enable the potential of multiple combination therapies."

The picoplatin data were presented today in a poster ses
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
5. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
6. Poniard Pharmaceuticals Receives Going Concern Qualification
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
9. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 The joint venture between Dignity ... emergency room in Chandler on Friday, May 1st. The ... which is also part of the Dignity Health and ... Dignity Health Arizona General Hospital Emergency Room hosted a ... and donated $5,000 to Campo Verde High School. ...
(Date:5/5/2015)... Falls Church, VA (PRWEB) May 06, 2015 ... with FDA Regulations, Make Social Media Your Most Powerful ... 24-25, 2015 – Washington, DC, http://www.fdanews.com/SocialMedia , ... , Marketers dream of social media’s reach. Patients are ... talking to their doctors about what they’ve discovered. , ...
(Date:5/5/2015)... Khaimah, UAE (PRWEB) May 05, 2015 ... Century , FZ LLC has announced that its dental ... enrollment for Store-A-Tooth™ increased once again--in April, 2015 –and ... 40th month of increased record volume and represents a ... for Provia’s dental stem cell biobank is conducted via ...
(Date:5/5/2015)... 2015 NCPDP announced today that ... program establishes a three-year commitment of strategic support for ... Elite Partners. “AmerisourceBergen has supported our multi-stakeholder forum over ... “and this is a wonderful continuation and expansion of ... trace AmerisourceBergen back to our very first Board of ...
(Date:5/5/2015)... New York, NY (PRWEB) May 05, 2015 ... Maternity Health IVF Clinic in Greece, an experienced ... evaluation and treatment of infertility for patients around the ... has partnered with VisitandCare.com. Greece unquestionably remains a global ... the most talented and hard-working fertility specialists in the ...
Breaking Medicine News(10 mins):Health News:Dignity Health and Adeptus Health Opened First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health Opened First Freestanding Emergency Room in Chandler, Arizona 3Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 2Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 3Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 4Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 3Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 2Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 3
... zero in (on) the modalities of a drug, capable of ... trials on animal models have revealed the capacity of the ... charge of energy production., ,'Many drugs block the ... who is the Werner E. Bachmann Collegiate Professor of Chemistry ...
... renowned medical specialist, NHS can be freed from its’ ... reconsidered before they are implemented. // It is amply ... may make matters worse for the deprived and under ... has led to low morale among Doctors and NHS ...
... has announced the launch of BARACLUDE? (entecavir) for ... its approval by the Drug Controller General of India. ... of chronic hepatitis B virus infection in adults with ... persistent elevations in serum aminotransferases (ALT or AST) or ...
... warned that hospitals are repeatedly failing to implement rules ... to patients //from contaminated surgical instruments. ,The ... in sets so they can be traced easily. Instead ... ,Dr Gill Morgan, chief executive of the NHS ...
... with medical services functioning smoothly and the institute's director ... and attending to patients - a day after the ... ,While health services normalised in AIIMS after doctors, ... their agitation last evening following the court order, the ...
... diseases that has affected everyone from Henry VIII to Christoper ... near the site of infection//. The primary sore first appears ... clear. , This is followed by generalized skin rash, ... few months or years later tertiary syphilis develops which destroys ...
Cached Medicine News:Health News:Autoimmune disorders studied in detail by U-M researchers. 2Health News:India Approves Baraclude? (entecavir) For ,Treatment Of Chronic HEPATITIS B 2
(Date:5/5/2015)... May 05, 2015 Research and Markets ... "Home Healthcare Global Market - Forecast to 2020" ... healthcare market is expected to reach more than $300+ ... The home healthcare equipment market is expected to ... services market. Home healthcare is gaining a tremendous attention ...
(Date:5/5/2015)... , May 5, 2015 Lymphatic pump ... with antibiotic treatment, according to a new study published ... Researchers performed LPT on infected ... levofloxacin, a popular antibiotic used to treat pneumonia. After ... disease free compared to only 25 percent of rats ...
(Date:5/5/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... present at the following conferences in May 2015: ... ,Date:            May 10, ... Officer ,Time:            1:45 ...
Breaking Medicine Technology:Global Home Healthcare Global Market 2015 - Forecast to 2020 for the $300 Billion Market 2Lymphatic Pump Treatment Enhances Antibiotic Effectiveness for Treating Pneumonia 2Oramed to Present at Upcoming Conferences 2Oramed to Present at Upcoming Conferences 3
... Calif. , July 15 Premier Inc., ... 67,000-plus other healthcare sites working together to achieve high ... of FDA-cleared Electronic Brachytherapy Systems, announced the execution of ... three-year contract for brachytherapy systems with Premier Purchasing Partners ...
... At the 2010 American Association of Physicists in Medicine (AAPM) ... , Elekta (booth #101) will showcase its broad array of ... Image Guided Radiation Therapy. , ... "At Elekta, intelligent solutions originate from collaboration with medical ...
Cached Medicine Technology:Xoft Announces Exclusive Contract With Premier for Electronic Brachytherapy 2Xoft Announces Exclusive Contract With Premier for Electronic Brachytherapy 3Elekta to Highlight Intelligent Cancer Management Solutions at 2010 AAPM Annual Meeting 2Elekta to Highlight Intelligent Cancer Management Solutions at 2010 AAPM Annual Meeting 3Elekta to Highlight Intelligent Cancer Management Solutions at 2010 AAPM Annual Meeting 4
Heavy curved shafts with 2 x 2 teeth and crisscross serrated 6 mm tying platform. Serrated handle with polished finish....
Serrated, 10 mm tips angled 30 degrees. Serrated cross action handle with polished finish....
Smooth 90 degree jaws with locking screw maintain proper stretch of sleeve for securing silicone bands....
Ergotec Vetriretinal Instrument System. 2 mm pointed black tips with 0.6 mm platform. 20 gauge shaft tapers to 23 gauge....
Medicine Products: